The approval was supported by data from the phase 3 POLYP 1 (N=138) and POLYP 2 (N=127) trials evaluating the efficacy and safety of Xolair in adults with nasal polyps who had an inadequate response to nasal corticosteroids.
ACE-1334 is a TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands.
Long-term oxygen therapy strongly recommended for adults with COPD, ILD who have severe chronic resting hypoxemia
Small data set indicates that adults with current or previous SARS-CoV-2 can develop hyperinflammatory syndrome.
The 56-week OSTRO trial evaluated the efficacy and safety of benralizumab, an interleukin-5 antagonist, in 413 adult patients with severe nasal polyposis.
The FDA has approved a prefilled pen formulation of Dupixent (dupilumab; Sanofi and Regeneron), providing another option for administering the treatment.
The FDA has granted Breakthrough Therapy designation to brensocatib (INS1007; Insmed) for the treatment of adults with non-cystic fibrosis bronchiectasis for reducing exacerbations.
The first patients have been dosed in a phase 1 trial evaluating a potential antibody therapy designed to treat coronavirus disease 2019. These patients received treatment at major medical centers in the US, including NYU Grossman School of Medicine and Cedars-Sinai in Los Angeles.
Hydroxychloroquine, chloroquine suggested for hospitalized patients with COVID-19, severe pneumonia.
Findings from patient-directed survey showed that the most commonly reported respiratory adverse events included dysphonia, increased sputum production, increased cough and dyspnea.
